Staff Members - Benha University
YKL-40: An Emerging Biomarker of Endothelial Dysfunction in Arteriogenic Erectile Dysfunction
• 2017
Publication Information
Authors
Hanan H. Sabry1, Ahmed H. Hamed1, Jehan H. Sabry2, Osama H. Abdel-Salam1
Keywords
Not Available
Journal
Not Available
Publisher
Not Available
Volume
Not Available
Issue
Not Available
Pages
Not Available
publication.type
International
Paper Link
Not Available
Supplementary Materials
Not Available
Abstract
Introduction
Endothelial dysfunction is a central etiologic factor in the development of atherosclerosis and systemic vascular disease, which includes erectile dysfunction.
YKL-40 has been suggested to be a new marker of inflammation, atherosclerosis, and endothelial dysfunction.
Aim
To estimate serum levels of YKL40, as a new serum marker of endothelial dysfunction, in patients with arteriogenic erectile dysfunction.
Methods
Hundred subjects including 50 with arteriogenic erectile dysfunction and 50 healthy as a control group were enrolled to the study. Serum YKL-40 levels were measured in patients and controls using ELISA technique.
Results
Serum YKL-40 levels was significantly elevated in arteriogenic ED patients compared with controls. Positive significant correlations were found between serum levels of YKL40 and patients’ age (r=0.588, p=0.001), duration of erectile dysfunction (r=0.673, p=0.001), BMI (r=0.598, p=0.001). The patients with hypertension had significantly elevated YKL-40 levels than those who were normotensive (164.88 ± 191.73 Vs 60.22 ± 26.44, respectively).
Conclusion
Serum levels of YKL-40 are elevated in arteriogenic ED patients denoting that endothelial dysfunction play a role in the pathogenesis of arteriogenic ED and YKL-40 as a novel marker of endothelial dysfunction could be a marker of arteriogenic erectile dysfunction.
Endothelial dysfunction is a central etiologic factor in the development of atherosclerosis and systemic vascular disease, which includes erectile dysfunction.
YKL-40 has been suggested to be a new marker of inflammation, atherosclerosis, and endothelial dysfunction.
Aim
To estimate serum levels of YKL40, as a new serum marker of endothelial dysfunction, in patients with arteriogenic erectile dysfunction.
Methods
Hundred subjects including 50 with arteriogenic erectile dysfunction and 50 healthy as a control group were enrolled to the study. Serum YKL-40 levels were measured in patients and controls using ELISA technique.
Results
Serum YKL-40 levels was significantly elevated in arteriogenic ED patients compared with controls. Positive significant correlations were found between serum levels of YKL40 and patients’ age (r=0.588, p=0.001), duration of erectile dysfunction (r=0.673, p=0.001), BMI (r=0.598, p=0.001). The patients with hypertension had significantly elevated YKL-40 levels than those who were normotensive (164.88 ± 191.73 Vs 60.22 ± 26.44, respectively).
Conclusion
Serum levels of YKL-40 are elevated in arteriogenic ED patients denoting that endothelial dysfunction play a role in the pathogenesis of arteriogenic ED and YKL-40 as a novel marker of endothelial dysfunction could be a marker of arteriogenic erectile dysfunction.